Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysis

CONCLUSION: The combination of ofatumumab, HDMP, and lenalidomide was effective and relatively well tolerated in treatment-naive CLL/SLL. Its role in the frontline setting remains unclear given the current available and effective treatment options.FUNDING: The funders had no role in the study.PMID:38508880 | DOI:10.1016/j.clml.2024.02.001

Source: Clinical Lymphoma and Myeloma - March 20, 2024 Category: Cancer & Oncology Authors: Julio C Chavez Ariel Grajales Jose Sandoval-Sus Elyce Turba Lisa Nodzon Angimar Uriepero-Palma Mohammad Ammad-Ud-Din Eva Sahakian Rami Komrokji Lubomir Sokol Frederick L Locke Bijal Shah Jeffrey Lancet Eduardo M Sotomayor Mohamed A Kharfan-Dabaja Celeste Source Type: research